Log In
Print
BCIQ
Print
Print this Print this
 

Ragweed Allergy Immunotherapy Tablet (AIT) (Ragwitek) (MK-3641) (formerly SCH 039641)

  Manage Alerts
Collapse Summary General Information
Company ALK-Abello A/S
DescriptionTablet-based sublingual allergen immunotherapy
Molecular Target
Mechanism of ActionImmunotherapy
Therapeutic ModalityBiologic
Latest Stage of DevelopmentMarketed
Standard IndicationAllergy
Indication DetailsTreat ragweed-induced allergic rhinitis; Treat ragweed-induced rhinoconjunctivitis
Regulatory Designation U.S. - Undisclosed Review (Treat ragweed-induced allergic rhinitis);
Canada - Standard Review (Treat ragweed-induced allergic rhinitis)
Partner Merck & Co. Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$81.4M

$40.7M

$40.7M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today